Asset Details
Do you wish to reserve the book?
Generic drugs in oncology – Authors' reply
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Generic drugs in oncology – Authors' reply
Do you wish to request the book?
Generic drugs in oncology – Authors' reply
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Generic drugs in oncology – Authors' reply
2017
Overview
[...]in the USA, 80% of reports on adverse event reported to the FDA's online database for the first three quarters of 2015 were for brand-name cancer medications, despite the high level of generic oncology pharmaceutical penetration.2 Nevertheless, quality concerns for generic oncology drugs (and more so for oncology biosimilars, which are not exact copies of the reference drug) exist in developing countries where oversight is less intensive.2,3 Measures to prevent counterfeit and substandard oncology generics in these countries should be rigorously monitored.
Publisher
Elsevier Ltd,Elsevier Limited
